Question 1

What is the ESG rating for LLY?

Accepted Answer

Eli Lilly and Company has the following ESG ratings: MSCI ESG Rating: A, Sustainalytics ESG Risk: 20, ESG Enterprise Score: 80.

Question 2

What are the main strengths of investing in LLY?

Accepted Answer

The main strengths of investing in Eli Lilly and Company include: Major insulin price cuts and programs improving global medicine access, Life-saving drug innovations with strong pipeline for public health benefits, Strong workplace inclusion frequently listed among best places to work.

Question 3

What are the potential drawbacks of investing in LLY?

Accepted Answer

Potential drawbacks of investing in Eli Lilly and Company include: Historical high drug pricing strategies draw ongoing scrutiny, Manufacturing environmental footprint requires continued reduction, Ensuring ethical marketing and patient safety remains paramount.

Question 4

What are the key financial metrics for LLY?

Accepted Answer

Key financial metrics for Eli Lilly and Company include: Market Cap: $2.63 billion, Current Price: $140.54, Dividend Yield: 0.77%.

Eli Lilly and Company

Detailed View

LLY

ESG Ratings